Evidence map›Paper›PMID 26973794›Full record

ArticleClinical hypertension2015

The utility of biomarker risk prediction score in patients with chronic heart failure.

Alexander E Berezin, Alexander A Kremzer, Yulia V Martovitskaya, Tatyana A Berezina, Tatyana A Samura

RetractedOpen access · diamondAbstract readRetracted Publication
In one paragraph

Article in Clinical hypertension, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
13.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 76 citations in OpenAlex.

  1. Article
  2. Observational
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Alexander E BerezinInternal Medicine Department, State Medical University, 26, Mayakovsky av, Zaporozhye,, UA-69035 Ukraine.ORCID 0000-0002-0446-3999
Alexander A KremzerClinical Pharmacology Department, State Medical University, Zaporozhye, Ukraine.
Yulia V MartovitskayaPathology Department, State Medical University, Zaporozhye, Ukraine.
Tatyana A BerezinaPrivate Medical Center "Vita-center", Zaporozhye, Ukraine.
Tatyana A SamuraClinical Pharmacology Department, State Medical University, Zaporozhye, Ukraine.
Zaporizhzhia State Medical and Pharmaceutical University · UA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic heart failure (CHF) has been remained a leading cause of cardiovascular morbidity and mortaluty. The risk stratification of CHF individuals based on clinical criteria and biomarkers' models may improve medical care and probably increase efficacy of treatment strategy. However, various predictive models approved for CHF patients appear to be distinguished in their prognostications. The study aim was to evaluate whether biomarker risk prediction score is powerful tool for risk assessment of three-year fatal and non-fatal cardiovascular events in CHF patients.

methodsIt was studied prospectively the incidence of fatal and non-fatal cardiovascular events in a cohort of 388 patients with ischemic-induced CHF within 3 years. Circulating biomarkers were collected at baseline of the study.

resultsIndependent predictors of clinical outcomes in patients with CHF were NT-pro-BNP, galectin-3, hs-CRP, osteoprotegerin, CD31(+)/annexin V(+) endothelail-derived microparticles (EMPs) and CD31(+)/annexin V(+) EMPs to CD14(+)CD309(+) monuclear progenitor cells (MPCs) ratio. Index of cardiovascular risk was calculated by mathematical summation of all ranks of independent predictors, which occurred in the patients included in the study. Kaplan-Meier analysis showed that patients with CHF and the magnitude of the risk of less than 4 units have an advantage in survival when compared with patients for whom obtained higher values of cardiovascular risk score ranks.

conclusionBiomarker risk score for cumulative cardiovascular events, constructed by measurement of circulating NT-pro-BNP, galectin-3, hs-CRP, osteoprotegerin, CD31+/annexin V+ EMPs and CD31(+)/annexin V(+) EMPs to CD14(+)CD309(+) MPCs ratio, allowing reliably predict the probability survival of patients with CHF.

Indexed as

BiomarkersCardiovascular outcomesChronic heart failurePredictive value

Identifiers

PMID26973794
PMCPMC4787185
OpenAlexW2516957014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.